Incyte has earned a Strong Buy rating from leading analysts, driven by a 56% stock rally over the past year that reflects robust top-line execution. The company’s earnings have more than doubled since 2021, fueled by its core hematology franchise and expanding dermatology and oncology businesses. Consensus revenue estimates for 2025 have been revised upward by 8% following back-to-back quarters of better-than-expected results, reinforcing investor confidence in management’s ability to sustain growth.

Sales of Jakafi rose 6.7% year-over-year in Q3 2025, countering earlier concerns of a terminal decline as the drug approaches its 2028 patent expiration. Meanwhile, Incyte’s non-Jakafi portfolio delivered 45% year-over-year revenue growth, driven largely by the rapid uptake of Opzelura in dermatology and early traction for emerging oncology candidates. Management projects that ex-Jakafi revenues will triple by 2030, targeting $3–4 billion in annual sales, with Jakafi XR expected to extend the franchise’s lifecycle and offset patent cliff headwinds.

Incyte’s late-stage pipeline features multiple potential catalysts through 2028, including Phase III readouts in myelofibrosis and novel checkpoint inhibitors for solid tumors. The company is targeting a 15–20% compound annual sales growth rate over the next five years, underpinned by margin improvement from higher-value specialty products. With R&D expenditures increasing 25% year-over-year to $1.2 billion in 2024, management has reiterated its commitment to disciplined investment in high-potential assets, positioning Incyte for sustained profitability and significant upside for long-term shareholders.